Tratamiento de la hepatitis crónica C con interferón alfa 2b recombinante. Ensayo clínico controlado aleatorizado

Revista Cubana de Medicina

Volumn 39, Issue 1, 2000, Pages 12-20

  Arús Soler, Enrique ^a   Rivera Reimón, Luis ^a,b   Fernández Naranjo, Anayda ^a,c   Infante Velázquez, Mirtha ^a,d   Diaz, Rafael Jorge ^a,e   Soto Argüelles, Grisel ^a,f   López Saura, Pedro ^a,g   Gra Oramas, Bienvenido ^a,h  

^a HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^b Hospital Militar Central Dr Carlos J Finlay   (Cuba)

^c Facultad de Ciencias Médicas Julios Trigo

^d INSTITUTO SUPERIOR DE MEDICINA MILITAR DR LUIS DÍAZ SOTO   (Cuba)

^e Hospital Militar Dr Mario Muñoz

^f Centro Nacional Coordinador de Ensayos Clinicos   (Cuba)

^g CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^h INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 32044437091     PISSN: 00347523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(Suppl 1):62S-65S.
2. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-4.
3. National Institute of Health, National Institute of Health Concensus. Development Conference Panel Statement: management of hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
4. Alter MJ. The epidemiology of acute and chronic hepatitis C. En: Davis GL, ed. Clinics in liver diseases. Philadelphia:WB Saunders, 1997:559-68.
5. Heintger T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997;26:521-6.
6. Takahashi M, Yamada G, Miyamoto R, Doi T, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240-3.
7. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpodes JJ, Alter HJ. Long term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
8. Mattson L, Weiland O, Glauman H. Long term follow-up chronic posttransfusion non-A, non-B hepatitis: clinical and histological outcome. Liver 1998;8:184-8.
9. Tremolada F, Casarin C, Alberti. Long term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
10. Yano M, Kumada H, Kage M. The long term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
11. Ostapowicz G, Watson KJ, Lacornivi SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730-5.
12. Working Group on the evaluation of carcinogenic risk to humans. International agency for research on cancer. World Health Organization. Monographs on the evaluation of carcinogenic risk to humans 1994;59:165-221.
13. Rao KV, Andersen RC. Long term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 1998;45:45-52.
14. Kirkman RL, Strom TB, Wein MR, Tiney NL. Late mortality and morbidity in recipients of long term renal allografts. Transplantation 1998;34:347-51.
15. Grotz WH, Peters TH, Schlayer HJ, et al. Immunosuppresive therapy and hepatitis C virus infection: the clinical course of liver disease. J Mol Med 1996;74:407-12.
16. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
17. Shiffman M, Pockros PJ, Reddy RK, Wrigh TL, Reindollar R, Fried MW, et al. A controlled, randomized, multicenter, ascending dose phase II trial of Pegylated interferon alfa 2a (PEG) standard interferon alpha 2a (IFN) for treatment of chronic hepatitis C. Plenary Session of American Association for the Study of the Liver, Digestive disease weeck (DDW-99) Annual meeting (Abstract book -version electrónica-). Orlando, Florida. EUA. Mayor 16-19 1999. (Abstract L418).
18. Lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha 2b. A multicenter study. Dig Dis Sci 1993;38:612-8.
19. Lin R, Roach E, Zimmerman M, Strasser S, Farrel GC. Interferon alpha 2b for chronic hepatitis C: effects of dose increment and duration of treatment and response rate. Results of the first multicentre Australian trial. J Hepatol 1995;23:487-96.
20. Hakosako Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
21. Mc Hutchison JG, Poynard T. Combination therapy with interferon plus Ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):57-65.
22. Davil GL. Combination therapy with interferon alpha and Ribavirin as treatment of interferon relapse in chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):49-55.
23. Desmet VJ, Gerber M, Hoofnagle JH, Manns Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
24. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymtomatic chronic active hepatitis. Hepatology 1981;1:431-5.
25. Shiffman M. Use of high -dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999;(Suppl 1):25-33.
26. Poynard T, Marcellin P, Lee S, Niederau Ch, Minuk G, Ideo G, et al. Randomized trial of interferon alpha 2b plus Ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
27. Poynard T, Bedosa P, Chevalier M, et al, and Multicentre Study Group. A comparison of three interferon alpha 2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
28. Saez-Royuela F, Porres JC, Moreno A. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991;13:327-31.
29. Mc Hutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha 2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
30. Marcellin P, Boyer N, Martinot M, Erlinger S. Interferon therapy in hepatitis C: benefits and limitations. En: Arroyo V, Bosh J, Bruguera M, Rodes J, eds. Therapy in liver disease. The patophysiological basis of therapy. Barcelona:Masson, 1997:309-16.
31. Tsubota A, Chayama K, Ikeda K. Factors predictive of response to interferon alpha therapy inscripcion hepatitis C virus infection. Hepatology 1994;19:1088-94.
32. Bosch O, Tapia L, Quiroga JA, Carrefio V. An escalating dose regime of recombinant interferon alpha 2a in the treatment chronic hepatitis C. J Hepatol 1993;17:146-9.
33. Shiffman ML, Hofmann CM, Luketic VA, Thompson EB, Sanyol AJ. Treatment of chronic hepatitis C with escalating doses of interferon alpha 2b increases both biochemical and virological response [abstract] Hepatology 1995;22:152a
34. Moldes O, Lebovics E, Casellas A, Braverman J, Rosenthal WS. Dose escalation of alpha interferon (IFN) therapy in chronic hepatitis C (CHC). V International Symposium on Viral hepatitis (Abstract book). Madrid. Jan30-Feb 1 1992;52(Abstract 99).
35. Lindsay KL, Davis G, Shiff E, et al. Long term response to higher doses of interferon alpha 2b treatment of patients with chronic hepatitis C a randomized multicenter trial. Hepatology 1993;18:(4pt2):28-32.
36. Enriquez J, Torras X, Miralles F, Martínez Cerezo FJ, Sancho Poch FJ, Buenestado J, et al. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viremia and histological activity. J Virol Hepatol 1995;2:181-7.
37. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, et al. Lack of benefit of scalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
38. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-80.
39. Arús E, Infante M, Padrón GJ, Morales MG, Gra B, Soto G, et al. Interferón alpha 2b recombinante en hepatitis C crónica: resultados del tratamiento y determinación de anticuerpos anti-interferón. Biotecnol Aplicada 1997;14:242-7.
40. Davis GI, Esteban-Mur R, Rustgi V, et al. Interferon alfa 2b alone or in combination with Ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
41. Reinhard O, Foberg V, Fryden A, et al. High sustained response rate and clearence of viremia inscripcion chronic hepatitis after treatment with interferon alpha 2b for 60 weeks. Hepatology 1994;19:280-5.
42. Fattovich G, Guistina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
43. Grimm I, Shaheen N. Can interferon prevent hepatocellular carcinomas in hepatitis C virus induced-cirrhosis? Gastroenterology 1996;110:2019-21.
44. Harper SE, Diestag JL. Can interferon alpha treatment prevent hepatocellular carcinoma in patients with chronic hepatitis infection and compensated cirrhosis? Hepatology 1996;23:930-3.